Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARX201
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
ARX201 is a long-acting, recombinant human growth hormone (hGH) analogue developed using Ambrx's proprietary ReCODE technology. This technology enables site-specific mono-PEGylation of the hGH molecule by incorporating a chemically unique amino acid, resulting in improved pharmacokinetic properties and allowing for less frequent dosing compared to conventional hGH therapies. ARX201 acts as an agonist at the growth hormone receptor (GHR), stimulating production of insulin-like growth factor I (IGF-I) and supporting normal metabolic and anabolic functions. The drug was co-developed by Ambrx and Merck Serono for the treatment of adult growth hormone deficiency (AGHD), with clinical trials demonstrating normalization of IGF-I levels with weekly injections and an acceptable safety profile[1][2][5][7].
- Other names
- peg-ahgh
02
Targets
GHR (Growth hormone receptor)
Beyond the preview
Go deeper on ARX201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARX201.